Up Is Down: Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine Approval

From the New England Journal of Medicine.

By Jerry Avorn, MD and Aaron S. Kesselheim, MD, JD, MPH.

SUMMARY: This NEJM Perspective examines an unprecedented role reversal in the COVID-19 vaccine approval process. In September 2020, nine pharmaceutical company leaders took the unusual step of pledging not to apply for vaccine approval until adequate trial data were available — signaling caution — while the federal government was simultaneously pushing to accelerate emergency authorization. Avorn and Kesselheim note that for decades, manufacturers had typically criticized the FDA for moving too slowly and requiring too much evidence, while the agency served as a brake on industry enthusiasm. During the pandemic, these roles appeared to reverse, with industry leaders concerned that rushed approval could damage public trust in both vaccines and drug makers. The authors use this inversion to examine what it reveals about the fragile politics of drug regulation and the stakes of maintaining credible, evidence-based standards.

BACKGROUND: For decades, pharmaceutical manufacturers had criticized the FDA for being too slow and requiring too much evidence before approving products. During the COVID-19 pandemic, this pattern appeared to reverse.

KEY FINDINGS: In September 2020, nine pharmaceutical company leaders pledged not to apply for COVID-19 vaccine approval until adequate trial data were available, fearing that rushed approval could damage public trust in both vaccines and the industry itself.

IMPLICATIONS: The episode illustrates the fragility of public trust in drug approval and the importance of maintaining credible, evidence-based regulatory standards even under political pressure.